Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Autosomal Dominant Juvenile Parkinson Disease

quinazolines has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bengoetxea, H; Bulnes, S; Lafuente, JV; Requejo, C; Ruiz-Ortega, JA; Ugedo, L1
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Hattori, K; Ishida, J; Iwashita, A; Kamijo, K; Kido, Y; Kinoshita, T; Matsuoka, N; Mihara, K; Miyake, H; Murano, K; Ohkubo, M; Teramura, Y; Yamamoto, H; Yamazaki, S1

Other Studies

3 other study(ies) available for quinazolines and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.
    Molecular neurobiology, 2018, Volume: 55, Issue:1

    Topics: Animals; Male; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2018
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Neuropharmacology, 2013, Volume: 73

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes

2013
Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.
    Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

    Topics: Administration, Oral; Animals; Biological Availability; Blood-Brain Barrier; Brain; Catalytic Domain; Combinatorial Chemistry Techniques; Dogs; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; Microsomes, Liver; Models, Molecular; Parkinsonian Disorders; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Structure-Activity Relationship

2004